A Phase 2 interventional study of Filgotinib and Placebo in Inflammatory Bowel Disease, sponsored by Lakefront Biotherapeutics NV. Terminated at 56 sites in 11 countries. Open to male participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Lakefront Biotherapeutics NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Inflammatory Bowel Diseases with a site in India — 3 open to participants now, 4 under way, 1 of them phase 3. Inflammatory Bowel Diseases · India.
Among the 14 studies in Inflammatory Bowel Diseases with a site in India, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 4th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.
Browse Inflammatory Bowel Diseases studies →3 of the 14 studies in Inflammatory Bowel Diseases with a site in India are open now. Recruiting first, the newest first:
Spyre Therapeutics, Inc. · Sites in India, United States, Argentina and 32 more countries
Ages 18–75
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Sites in India, United States, Australia and 25 more countries
Ages 18–85
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 21 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 315 across the 14 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Lakefront Biotherapeutics NV is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Lakefront Biotherapeutics NV has 2 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Inflammatory Bowel Diseases with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Inflammatory Bowel Diseases with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease (IBD).
Results of this study may be pooled with the results of a separate study being conducted in participants with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis (Protocol GLPG0634-CL-227; NCT03926195) with the same objective. The total planned number of participants in both studies combined will be up to approximately 250 participants.
There are 5 parts to the study: 1) Part A: Double-Blind Phase (DB Phase; Day 1 through Week 13); 2) Part B: DB Phase (after Week 13 through Week 26); 3) Open-label (OL) Filgotinib Phase (after Week 13 study visit for up to 13 weeks); 4) Monitoring Phase (MP; up to 52 weeks); and 5) Long-term Extension (LTE) Phase (after Week 26 or end of OL Filgotinib Phase for up to 195 weeks).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received filgotinib up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to a standard of care (SOC) regimen selected by the investigator and entered the MP for up to 52 weeks.
Drug: Filgotinib · Drug: Standard of Care
Participants received placebo (matched to filgotinib) up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to SOC regimen selected by the investigator and entered the MP for up to 52 weeks.
Drug: Placebo · Drug: Standard of Care
200 mg tablet administered orally once daily
Placebo to match filgotinib tablet administered orally once daily
Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13
Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperm cells/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.
Time frame: Baseline to Week 13
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26
IBD responder: For ulcerative colitis (UC), a participant who had a reduction of ≥2 in partial Mayo Clinic Score (pMCS) compared with baseline at specified time. For Crohn's disease (CD), a participant who had a reduction of ≥100 points in total Crohn's Disease Activity Index (CDAI) score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥220 to ≤250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm concentration is ≥15 million sperm cells/mL.
Time frame: Baseline to Week 26
Change From Baseline in Sperm Total Motility at Week 13
The normal range for sperm total motility is ≥40%.
Time frame: Baseline, Week 13
Change From Baseline in Sperm Total Motility at Week 26
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm total motility is ≥40%.
Time frame: Baseline, Week 26
Change From Baseline in Total Sperm Count at Week 13
The normal range for total sperm count is ≥ 39 million sperm cells/ejaculate.
Time frame: Baseline, Week 13
Change From Baseline in Total Sperm Count at Week 26
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for total sperm count is ≥ 39 million sperm cells/ejaculate.
Time frame: Baseline, Week 26
Change From Baseline in Sperm Concentration at Week 13
The normal range for sperm concentration is ≥15 million sperm cells/mL.
Time frame: Baseline, Week 13
Change From Baseline in Sperm Concentration at Week 26
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm concentration is ≥15 million sperm cells/mL.
Time frame: Baseline, Week 26
Change From Baseline in Ejaculate Volume at Week 13
The normal range for ejaculate volume is ≥1.5 mL.
Time frame: Baseline, Week 13
Change From Baseline in Ejaculate Volume at Week 26
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for ejaculate volume is ≥1.5 mL.
Time frame: Baseline, Week 26
Change From Baseline in Percent Normal Sperm Morphology at Week 13
The normal range for percent normal sperm morphology is ≥30% normal sperms.
Time frame: Baseline, Week 13
Change From Baseline in Percent Normal Sperm Morphology at Week 26
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for percent normal sperm morphology is ≥30% normal sperms.
Time frame: Baseline, Week 26
Participants were enrolled at study sites in Australia, Austria, Germany, India, New Zealand, Poland, Romania, Russian Federation, Ukraine, United Kingdom, and United States. The first participant was screened on 11 July 2017. A total of 323 participants were screened of which 139 participants were randomized into the study.
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 69 | 70 |
| Completed | 68 | 67 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 45 | 38 |
| Completed | 42 | 38 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Progressive disease | 2 | 0 |
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 24 | 23 |
| Completed | 22 | 20 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 38 | 34 |
| Completed | 8 | 5 |
| Not completed | 30 | 29 |
| Withdrew: Adverse event | 9 | 10 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Pre-specified decrease in sperm parameters (switched to mp) | 6 | 7 |
| Withdrew: Study terminated by sponsor | 11 | 5 |
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 18 | 16 |
| Completed | 0 | 2 |
| Not completed | 18 | 14 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Pre-specified decrease in sperm parameters (switched to mp) | 5 | 3 |
| Withdrew: Progressive disease | 2 | 0 |
| Withdrew: Study terminated by sponsor | 6 | 6 |
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 15 | 21 |
| Completed | 14 | 19 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperm cells/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.
| percentage of participants | Filgotinib | Placebo |
|---|---|---|
| Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13 | 1.5 | 9.0 |
IBD responder: For ulcerative colitis (UC), a participant who had a reduction of ≥2 in partial Mayo Clinic Score (pMCS) compared with baseline at specified time. For Crohn's disease (CD), a participant who had a reduction of ≥100 points in total Crohn's Disease Activity Index (CDAI) score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥220 to ≤250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm concentration is ≥15 million sperm cells/mL.
| percentage of participants | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26 | 5.0 | 0 | 7.9 | 11.8 |
The normal range for sperm total motility is ≥40%.
| percentage of motile sperms | Filgotinib | Placebo |
|---|---|---|
| Change From Baseline in Sperm Total Motility at Week 13 | -0.3 (-1.6 to 1.7) | 0.4 (-1.3 to 1.5) |
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm total motility is ≥40%.
| percentage of motile sperms | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Sperm Total Motility at Week 26 | -2.3 (-4.7 to -0.3) | -1.5 (-5.8 to 2.6) | 0.0 (-3.4 to 2.4) | 0.8 (-7.3 to 5.8) |
The normal range for total sperm count is ≥ 39 million sperm cells/ejaculate.
| million sperm cells/ejaculate | Filgotinib | Placebo |
|---|---|---|
| Change From Baseline in Total Sperm Count at Week 13 | -11.6 (-19.8 to 9.7) | -9.5 (-23.8 to 0.6) |
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for total sperm count is ≥ 39 million sperm cells/ejaculate.
| million sperm cells/ejaculate | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Total Sperm Count at Week 26 | 2.0 (-19.6 to 17.2) | -4.6 (-42.3 to 18.3) | -4.1 (-39.8 to 15.9) | 12.7 (-61.4 to 40.8) |
The normal range for sperm concentration is ≥15 million sperm cells/mL.
| million sperm cells/mL | Filgotinib | Placebo |
|---|---|---|
| Change From Baseline in Sperm Concentration at Week 13 | 1.0 (-2.2 to 3.9) | 0.7 (-2.7 to 1.7) |
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for sperm concentration is ≥15 million sperm cells/mL.
| million sperm cells/mL | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Sperm Concentration at Week 26 | 1.2 (-3.2 to 10.8) | -0.6 (-8.5 to 23.0) | 0.8 (-2.4 to 5.3) | -3.7 (-11.1 to 15.7) |
The normal range for ejaculate volume is ≥1.5 mL.
| mL | Filgotinib | Placebo |
|---|---|---|
| Change From Baseline in Ejaculate Volume at Week 13 | -0.2 (-0.3 to 0.1) | -0.1 (-0.3 to 0.0) |
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for ejaculate volume is ≥1.5 mL.
| mL | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Ejaculate Volume at Week 26 | 0.0 (-0.5 to 0.2) | -0.3 (-0.8 to 0.2) | -0.2 (-0.5 to 0.1) | -0.1 (-0.7 to 0.4) |
The normal range for percent normal sperm morphology is ≥30% normal sperms.
| percentage of normal sperms | Filgotinib | Placebo |
|---|---|---|
| Change From Baseline in Percent Normal Sperm Morphology at Week 13 | 2 (-1 to 4) | 1 (-1 to 2) |
IBD responder: For UC, a participant who had a reduction of ≥ 2 in pMCS compared with baseline at specified time. For CD, a participant who had a reduction of ≥ 100 points in total CDAI score compared with baseline at specified time. A participant with a baseline total CDAI score of ≥ 220 to ≤ 250 was considered an IBD responder if a CDAI score of \<150 was attained at specified time. IBD nonresponder: For UC or CD, a participant who did not fulfil the definition of IBD responder at specified time. pMCS score: Sum of 3 subscores (rectal bleeding, stool frequency, and physician's global assessment) excluding endoscopic subscore; ranging from 0 (none) to 9 (severe disease). CDAI score: A weighted sum of 8 disease activity variables with scores ranging from 0 to over 600, where higher score = higher disease activity. The normal range for percent normal sperm morphology is ≥30% normal sperms.
| percentage of normal sperms | Filgotinib/DB Filgotinib (Responder) | Filgotinib/OL Filgotinib (Nonresponder) | Placebo/DB Placebo (Responder) | Placebo/OL Filgotinib (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Percent Normal Sperm Morphology at Week 26 | 3 (1 to 5) | 1 (-2 to 3) | 2 (-4 to 5) | 2 (-2 to 3) |
Collected over From first dose up to Week 226. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib | 0/92 (0%) | 3/92 (3.3%) | 47/92 (51.1%) |
| Placebo | 0/70 (0%) | 2/70 (2.9%) | 24/70 (34.3%) |
| Event | Filgotinib | Placebo |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/92 | 1/70 |
| COVID-19Infections and infestations | 0/92 | 1/70 |
| Crohn's diseaseGastrointestinal disorders | 1/92 | 0/70 |
| PneumoniaInfections and infestations | 1/92 | 0/70 |
| Event | Filgotinib | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 17/92 | 3/70 |
| Colitis ulcerativeGastrointestinal disorders | 14/92 | 3/70 |
| COVID-19Infections and infestations | 9/92 | 3/70 |
| HeadacheNervous system disorders | 7/92 | 0/70 |
| GastritisGastrointestinal disorders | 7/92 | 1/70 |
| Latent tuberculosisInfections and infestations | 5/92 | 5/70 |
| Abdominal painGastrointestinal disorders | 3/92 | 5/70 |
| FuruncleInfections and infestations | 1/92 | 4/70 |
| PyrexiaGeneral disorders | 5/92 | 4/70 |
The Safety Analysis Set included all randomized participants who took ≥ 1 dose of double-blind study drug.
| Age, Continuous(years) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 36 ± 8.5 | 34 ± 8.4 | 35 ± 8.5 |
| Sex: Female, Male(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 69 | 70 | 139 |
| Race/Ethnicity, Customized(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 68 | 68 | 136 |
| Ethnicity — Hispanic or Latino | 1 | 1 | 2 |
| Ethnicity — Not Permitted | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 2 | 0 | 2 |
| Race — Asian | 37 | 38 | 75 |
| Race — Black or African American | 1 | 0 | 1 |
| Race — White | 29 | 31 | 60 |
| Race — Not Permitted | 0 | 1 | 1 |
| Sperm Concentration(million sperm cells/milliliter (mL)) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 63.4 ± 34.34 | 61.8 ± 34.96 | 62.6 ± 34.53 |
| Total Sperm Count(million sperm cells/ejaculate) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 190.6 ± 107.08 | 171.1 ± 100.74 | 180.8 ± 104.02 |
| Sperm Total Motility(percentage of motile sperm) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 59.6 ± 11.33 | 58.6 ± 10.94 | 59.1 ± 11.11 |
| Ejaculate Volume(mL) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 3.2 ± 1.20 | 3.0 ± 1.48 | 3.1 ± 1.35 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Nov 2020, 40 months.
Results were first posted in Dec 2023, 3 years after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634
Lakefront Biotherapeutics NV →